| Description |
Cixutumumab (IMC-A12) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer[1].
|
| Related Catalog |
|
| Target |
IGF-1R[1].
|
| In Vitro |
Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells[1]. Cell Viability Assay[1] Cell Line: CHLA-9, TC-71, Rh41 cells Concentration: 0.01-100 nM Incubation Time: 96 h Result: Inhibited CHLA-9, TC-71and Rh41 cells growth with IC50 values of 49.31, 0.66 and 0.04 nM, respectively.
|
| In Vivo |
Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels[1]. Animal Model: CB17SC-M scid-/- female mice (solid tumor xenografts model)[1]. Dosage: 1 mg/rat Administration: Intraperitoneal injection; twice weekly for 6 weeks. Result: Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.
|
| References |
[1]. Houghton PJ, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6.
|
